GHK is the standalone Glycyl-L-Histidyl-L-Lysine tripeptide
Manshouri T, Kala SV, Ashoori F, Zingaro R, Freireich EJ, Andreeff M , Kantarjian HM, Verstovsek S
In a mechanism of action study that aimed to achieve 10% body weight reduction in participants with obesity who were without T2D, tirzepatide was compared to placebo for sleeping and 24-h energy expenditure and respiratory exchange ratio by utilizing metabolic chambers assessed at baseline and after 18 weeks [56]
Drugs included in the pilot program are Eli Lillys oral obesity medication Orforglipron, the Zepbound QuickPen formulation, as well as Wegovy and oral Wegovy formulations
Pill versions may be available for some GLP-1 medications if you do not like or cannot take injections
Until those studies exist, GHK-Cu remains a fascinating molecule with strong preclinical credentials, proven topical skin benefits, and unresolved systemic therapeutic potential